TY - JOUR
T1 - Applying Amide Proton Transfer MR Imaging to Hybrid Brain PET/MR
T2 - Concordance with Gadolinium Enhancement and Added Value to [18F]FDG PET
AU - Sun, Hongzan
AU - Xin, Jun
AU - Zhou, Jinyuan
AU - Lu, Zaiming
AU - Guo, Qiyong
N1 - Funding Information:
Funding Information This work was supported in part by grants from the National Natural Science Foundation of China (Grant No. 81401438) and from the National Institutes of Health (R01EB009731, R01CA166171, R01NS083435).
Publisher Copyright:
© 2017, World Molecular Imaging Society.
PY - 2018/6/1
Y1 - 2018/6/1
N2 - Purpose: The purpose of this study is to evaluate the diagnostic concordance and metric correlations of amide proton transfer (APT) imaging with gadolinium-enhanced magnetic resonance imaging (MRI) and 2-deoxy-2-[18F-]fluoro-D-glucose ([18F]FDG) positron emission tomography (PET), using hybrid brain PET/MRI. Procedures: Twenty-one subjects underwent brain gadolinium-enhanced [18F]FDG PET/MRI prospectively. Imaging accuracy was compared between unenhanced MRI, MRI with enhancement, APT-weighted (APTW) images, and PET based on six diagnostic criteria. Among tumors, the McNemar test was further used for concordance assessment between gadolinium-enhanced imaging, APT imaging, and [18F]FDG PET. As well, the relation of metrics between APT imaging and PET was analyzed by the Pearson correlation analysis. Results: APT imaging and gadolinium-enhanced MRI showed superior and similar diagnostic accuracy. APTW signal intensity and gadolinium enhancement were concordant in 19 tumors (100 %), while high [18F]FDG avidity was shown in only 12 (63.2 %). For the metrics from APT imaging and PET, there was significant correlation for 13 hypermetabolic tumors (P < 0.05) and no correlation for the remaining six [18F]FDG-avid tumors. Conclusions: APT imaging can be used to increase diagnostic accuracy with no need to administer gadolinium chelates. APT imaging may provide an added value to [18F]FDG PET in the evaluation of tumor metabolic activity during brain PET/MR studies.
AB - Purpose: The purpose of this study is to evaluate the diagnostic concordance and metric correlations of amide proton transfer (APT) imaging with gadolinium-enhanced magnetic resonance imaging (MRI) and 2-deoxy-2-[18F-]fluoro-D-glucose ([18F]FDG) positron emission tomography (PET), using hybrid brain PET/MRI. Procedures: Twenty-one subjects underwent brain gadolinium-enhanced [18F]FDG PET/MRI prospectively. Imaging accuracy was compared between unenhanced MRI, MRI with enhancement, APT-weighted (APTW) images, and PET based on six diagnostic criteria. Among tumors, the McNemar test was further used for concordance assessment between gadolinium-enhanced imaging, APT imaging, and [18F]FDG PET. As well, the relation of metrics between APT imaging and PET was analyzed by the Pearson correlation analysis. Results: APT imaging and gadolinium-enhanced MRI showed superior and similar diagnostic accuracy. APTW signal intensity and gadolinium enhancement were concordant in 19 tumors (100 %), while high [18F]FDG avidity was shown in only 12 (63.2 %). For the metrics from APT imaging and PET, there was significant correlation for 13 hypermetabolic tumors (P < 0.05) and no correlation for the remaining six [18F]FDG-avid tumors. Conclusions: APT imaging can be used to increase diagnostic accuracy with no need to administer gadolinium chelates. APT imaging may provide an added value to [18F]FDG PET in the evaluation of tumor metabolic activity during brain PET/MR studies.
KW - APT imaging
KW - Brain
KW - Gd contrast
KW - PET/MR
KW - [F]FDG
UR - http://www.scopus.com/inward/record.url?scp=85031912635&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85031912635&partnerID=8YFLogxK
U2 - 10.1007/s11307-017-1136-0
DO - 10.1007/s11307-017-1136-0
M3 - Article
C2 - 29063304
AN - SCOPUS:85031912635
SN - 1536-1632
VL - 20
SP - 473
EP - 481
JO - Molecular Imaging and Biology
JF - Molecular Imaging and Biology
IS - 3
ER -